Moreover, intranasal administration of recombinant galectin-1 during influenza virus infection reduced viral load and accompanying inflammation, tissue damage, and mortality in the murine model, and galectin-1 null mice were more susceptible to influenza infection than wildtype mice. Here, LGALS1 is linked to influenza.